Zomedica Pharmaceuticals Ownership
| ZOM Stock | USD 0.13 0.01 8.33% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 949.9 M | Current Value 979.9 M | Avarage Shares Outstanding 361 M | Quarterly Volatility 425.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Zomedica |
Zomedica Stock Ownership Analysis
The company has Price to Book (P/B) ratio of 0.55. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zomedica Pharmaceuticals recorded a loss per share of 0.03. The entity had not issued any dividends in recent years. Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan. Zomedica Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on AMEX Exchange. It employs 47 people. For more information please call Robert Cohen at 734 369 2555 or visit https://www.zomedica.com.Besides selling stocks to institutional investors, Zomedica Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Zomedica Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Zomedica Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Zomedica Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Only 1.59% of Zomedica Pharmaceuticals Corp are currently held by insiders. Unlike Zomedica Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Zomedica Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Zomedica Pharmaceuticals' insider trades
Zomedica Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zomedica Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zomedica Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zomedica Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Shameze Rampertab over a month ago Insider Trading | ||
Anthony Blair over a month ago Disposition of 3000000 shares by Anthony Blair of Zomedica Pharmaceuticals at 0.35 subject to Rule 16b-3 | ||
Russell Klass over a month ago Acquisition by Russell Klass of 2000000 shares of Zomedica Pharmaceuticals at 0.19 subject to Rule 16b-3 | ||
Johnny Powers over three months ago Purchase by Johnny Powers of 100000 shares of Zomedica Pharmaceuticals | ||
Johnny Powers over three months ago Purchase by Johnny Powers of 100000 shares of Zomedica Pharmaceuticals | ||
Johnny Powers over three months ago Purchase by Johnny Powers of 150000 shares of Zomedica Pharmaceuticals | ||
Johnny Powers over six months ago Purchase by Johnny Powers of 100000 shares of Zomedica Pharmaceuticals |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for Zomedica Stock analysis
When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.026 | Quarterly Revenue Growth 0.192 | Return On Assets (0.07) | Return On Equity (0.14) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.